LWP
BMRN icon

Laurel Wealth Planning’s BioMarin Pharmaceuticals BMRN Stock Holding History

Laurel Wealth Planning’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,150
Closed -$119K – 81
2022
Q4 		$119K Hold
1,150
– – 0.08% 76
2022
Q3 		$97K Hold
1,150
– – 0.07% 80
2022
Q2 		$95K Hold
1,150
– – 0.07% 81
2022
Q1 		$89K Buy
+1,150
New +$96.2K 0.06% 97

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Laurel Wealth Planning's BMRN Position: Q1 2023 in Review

Laurel Wealth Planning sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2023, closing a stake of 1,150 shares — an estimated $119K sold.

Laurel Wealth Planning first reported a position in BMRN in Q1 2022 and held it in 4 quarters. The position peaked at $119K in Q4 2022. 552 funds tracked by Wall St. Rank hold BMRN as of Q1 2023.

  • Laurel Wealth Planning reported no remaining BioMarin Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Laurel Wealth Planning sold 1,150 BioMarin Pharmaceuticals shares in Q1 2023, an estimated $119K.
  • Laurel Wealth Planning first reported a position in BioMarin Pharmaceuticals in Q1 2022 and held it in 4 quarters.
  • Laurel Wealth Planning's BioMarin Pharmaceuticals position peaked at $119K in Q4 2022.
  • 552 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2023.

Based on Laurel Wealth Planning's 13F filing for Q1 2023, filed 18 Apr 2023.